Please login to the form below

Not currently logged in
Email:
Password:

Akarna Therapeutics

This page shows the latest Akarna Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Gilead chalks up trial success for new NASH drug

Gilead chalks up trial success for new NASH drug

Along with selonsertib, Gilead is also developing an FXR agonist called GS-9674 in phase I trials and acquired a wholly-owned subsidiary of Nimbus Therapeutics for $1.2bn earlier this ... Allergan has been building a pipeline of candidates through a

Latest news

  • Allergan buys two NASH drug developers in one day Allergan buys two NASH drug developers in one day

    More than $1.7bn paid for Tobira Therapeutics and Akarna Therapeutics.  Allergan has gone on the acquisition trail once again, stumping up more than $1.7bn for non-alcoholic steatohepatitis (NASH) ... drug developers Tobira Therapeutics and Akarna

More from news
Approximately 2 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    Closing on the same day as the Tobira deal, Allergan also paid $50m upfront with milestones to follow to buy Akarna Therapeutics, bringing AKN-083, a preclinical farnesoid X receptor (FXR) ... 639. Cynapsus Therapeutics / Sunovion. Acquisition corporate.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Enterprise Therapeutics appoints CEO Enterprise Therapeutics appoints CEO

    Previously, Dr Ford has worked as general manager of Akarna Therapeutics' UK operations, chief operating officer of Dezima Pharma and a team leader for cell-based drug discovery campaigns at BioFocus ... Discovery. Dr Peter Finan, chairman of Enterprise

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics